4-[4-(2-fluoro-4-methoxy-phenyl)-thiazol-2-yl]-piperidine hydrobromide | 926891-52-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-[4-(2-fluoro-4-methoxy-phenyl)-thiazol-2-yl]-piperidine hydrobromide
• 英文别名: 4-(2-Fluoro-4-methoxyphenyl)-2-piperidin-4-yl-1,3-thiazole;hydrobromide
• CAS: 926891-52-3
• 化学式: BrH*C₁₅H₁₇FN₂OS
• 分子量: 373.289
• InChiKey: KMQZRIVJLAUNFZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.0
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  62.4
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Thiazolyl piperidine derivatives
  申请人：Nettekoven Heinrich Matthias

  公开号：US20070043083A1

  公开（公告）日：2007-02-22

  The present invention relates to compounds of formula I wherein R 1 , R 2 and R 3 are as defined in the description and claims. It further relates to pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及公式I中的化合物，其中R1、R2和R3如描述和索赔中所定义。它还涉及其药学上可接受的盐，以及包含这些化合物的药物组合物和其制备方法。这些化合物可用于治疗和/或预防与H3受体调控相关的疾病。
• THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1945635B1

  公开（公告）日：2009-05-06
• US7786143B2
  申请人：——

  公开号：US7786143B2

  公开（公告）日：2010-08-31
• [EN] THIAZOLYL PIPERIDINE DERIVATIVES<br/>[FR] DERIVES DE THIAZOLYLPIPERIDINES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2007020213A2

  公开（公告）日：2007-02-22

  [EN] The present invention relates to compounds of formula (I) wherein R¹, R² and R³ are as defined in the description and claims. It further relates to pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
  [FR] L'invention concerne des composés de formule (I), dans laquelle R¹, R² et R³ sont tels que définis dans la description et les revendications. L'invention concerne en outre des sels pharmaceutiquement acceptables de ces composés, ainsi que des compositions pharmaceutiques comprenant ces composés et des procédés de préparation de ceux-ci. Les composés selon l'invention sont utiles pour traiter et/ou prévenir des maladies associées à la modulation des récepteurs H3.